The NeoantigenID analytic module processes the raw DNA and RNA data to provide an extensive evaluation of candidate neoantigens derived from SNVs, indels, and/or fusions. Significantly, both in-frame and out-of-frame events are accurately considered by transcript, ensuring that a potentially-rich source of putative neoantigens are captured.
Figure 2: Workflow of the NeoantigenID Analytics Engine
The NeoantigenID deliverables used to prioritize neoantigen targets for PCV and/or PACT development are as follows:
- Identification and ranking of neoantigens based on information such as HLA typing, MHC-binding prediction, similarity-to-self, similarity-to-known antigens, and immunogenicity
- Allelic fraction and gene- and variant-level expression
- Phasing for allele-specific expression determination
|Gene Symbol||Peptide||HLA||Variant Source Type||Expressed||AF DNA||AF RNA||Minimum Binding Affinity (nM)||Predictor||Binding Pocket Sequence||Immuno-genicity|
Table 1: Example of the information delivered via NeoantigenID for each of the potentially immunogenic neoantigens identified.